Novo Nordisk CEO Mike Doustdar is facing investors and analysts under pressure to rebuild confidence in the company’s long-term growth strategy after concerns over its drug pipeline overshadowed an improved 2026 financial outlook. The Danish pharmaceutical giant raised its full-year sales and profit forecasts on Tuesday, but investor attention focused instead on weaker-than-expected early sales of its new Wegovy obesity pill and setbacks involving its next-generation obesity treatment, CagriSema. Following the announcement, Novo Nordisk shares fell 3.7% in early trading in Copenhagen on Wednes

Novo Nordisk CEO Mike Doustdar is facing investors and analysts under pressure to rebuild confidence in the company’s long-term growth strategy after concerns over its drug pipeline overshadowed an improved 2026 financial outlook.

The Danish pharmaceutical giant raised its full-year sales and profit forecasts on Tuesday, but investor attention focused instead on weaker-than-expected early sales of its new Wegovy obesity pill and setbacks involving its next-generation obesity treatment, CagriSema.

Following the announcement, Novo Nordisk shares fell 3.7% in early trading in Copenhagen on Wednesday, after its U.S.-listed shares dropped around 6% the previous day. The company’s stock has recovered about 30% from its March low but remains well below its 2024 peak, when Novo Nordisk became Europe’s most valuable listed company.

Doustdar, who has been leading efforts to turn around the company’s performance, said Novo Nordisk remains focused on expanding its research pipeline. He added that the company is considering smaller acquisitions rather than major transformative deals.

Pipeline Growth Becomes Investor Priority

Investors are increasingly concerned about Novo Nordisk’s ability to maintain growth beyond semaglutide, the active ingredient behind its blockbuster diabetes and obesity medicines, including Wegovy and Ozempic.

Analysts say the company needs a stronger pipeline as patents on key medicines approach expiration.

The latest disappointment came after trial setbacks involving CagriSema, a potential next-generation obesity drug, as well as the failure of cardiovascular medicine ziltivekimab in a clinical trial.

Doustdar said the setbacks would not change the company’s strategy but would push Novo Nordisk to increase research efforts and explore more opportunities.

“Our job is to make sure we increase the speed and the shots at goal when it comes to research and development,” Doustdar said.

Wegovy Pill Shows Strong Market Entry

Despite investor concerns, Novo Nordisk reported strong early demand for its oral Wegovy pill, which has launched in the United States, Britain and the United Arab Emirates.

Doustdar said the pill has captured around 90% of the oral obesity treatment market so far, despite competition from rival products developed by U.S. pharmaceutical company Eli Lilly.

Novo plans to introduce the pill in Germany soon after receiving European regulatory approval earlier this year.

Restructuring and Future Strategy

Novo Nordisk’s leadership said the company has no plans for another major cost-cutting programme after reducing its workforce by around 9,000 jobs during last year’s restructuring.

Chief Financial Officer Carsten Munk Knudsen said the priority now is strengthening the company’s research pipeline while maintaining productivity.

As Novo Nordisk continues to dominate the global obesity and diabetes medicine market, investors are watching closely to see whether the company can develop new blockbuster treatments and maintain its position in an increasingly competitive pharmaceutical industry.

A little more informed. A little more connected.